Document text
Principal Investigator: Mary N. Carrington
Organization: DIVISION OF BASIC SCIENCES - NCI
Fiscal Year: 2023
Award: $127,700
Funding agency: National Cancer Institute
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the ongoing COVID-19 pandemic. The pandemic's impact has spurred research into the pathogenesis, diagnosis, treatment, and prevention of SARS-CoV-2 and its emerging variants of concern. Prior studies have elucidated the role of neutralizing antibody responses to SARS-CoV-2 and the emergence of viral variants that escape these responses via mutations in spike protein. In addition, the critical role of T-cell responses against SARS-CoV-2 has also been well-established. However, research addressing the role of natural killer (NK) cells, in SARS-CoV-2 infection is limited. NK cells and some CD8+ T-cell subsets express a variety of germline-encoded activating and inhibitory receptors, which are broadly classified into three families: natural cytotoxicity receptors (e.g., NKp46), killer-cell immunoglobulin-like receptors (KIRs), and C-type lectin NK group 2 (NKG2) receptors. Activating receptors, such as NKG2D, can bind a variety of ligands expressed in the context of cellular stress. NKG2D is a potent activating receptor expressed on virtually all cytotoxic lymphocytes, both NK cells and CD8+ T cells. NKG2D uniquely signals through the adaptor molecule DAP10 and binds to eight known ligands: major histocompatibility complex class I chain-related proteins A (MIC-A) and B (MIC-B) and UL16-binding proteins 1-6 (ULBP-1-6). These ligands are expressed in response to cellular stress induced by infection or tumorigenesis, facilitating NK and CD8 T-cell recognition and killing via NKG2D. These ligands are targeted and downmodulated by many viruses, including herpesviruses, hepatitis viruses, and influenza virus, as well as by cancer cells, to escape immune recognition and killing. Previous data have also shown that in several infectious and malignant contexts NKG2D ligand shedding increases systemic levels of soluble ligands, which induces NKG2D receptor downregulation and impairs responsiveness and activity of both NK cells and CD8+ T cells. Studies analyzing immune responses in severe COVID-19 patients have revealed downregulation of NKG2D on circulating NK and CD8+ T cells as well as impaired function of these cells. As such, given the involvement of NKG2D in cytotoxic immune cells, it is important to study if and how this axis is modulated by SARS-CoV-2 and other coronaviruses. In collaboration with investigators at the Ragon Institute, the effect of SARS-CoV-2 infection on NKG2D ligand modulation was investigated and it was found that SARS-CoV-2 and its variants downregulate NKG2D ligands, including MIC-A/B, from the surface of infected cells. Further, this surface downregulation is the result of proteolytic cleavage mediated by endogenous sheddases, which were found to be transcriptionally induced by SARS-CoV-2 infection. This occurs despite transcriptional induction of MICB mRNA and increased overall MIC-A/B whole-cell protein levels. It was confirmed that SARS-CoV-2 infection transcriptionally induces MICB and the sheddase MMP9 in human lung xenografts, and sera from COVID-19 patients showed significantly increased levels of soluble MIC-A and MIC-B, with MIC-A levels associating with disease severity. To identify viral protein responsible for this effect, all 32 SARS-CoV-2 proteins in their native form were individually expressed (i.e., no tags) via mRNA transfection. Only ORF6, an accessory protein specific to mammalian sarbecoviruses, was capable of downregulating MIC-A/B via shedding similar to live virus infection. Despite evasion from NKG2D recognition, NK cells were still able to efficiently recognize and kill SARS-CoV-2-infected cells and also protect bystander cells from SARS-CoV-2 infection in vitro, indicating protective NK cell mechanisms against the virus beyond NKG2D alone. Remarkably, inhibition of MIC-A/B shedding in SARS-CoV-2-infected cells with 7C6, a monoclonal antibody in pre-clinical studies for the treatment of cancer, resulted in further increased NK-cell killing and degranulation, highlighting its potential role as a novel immunotherapy for COVID-19. Altogether, the data demonstrate a novel strategy that SARS-CoV-2 employs to evade NK-cell immunity, mediated by ORF6 accessory protein that is shared among sarbecoviruses, and suggest a potential target for immunotherapy to subvert the immunevasive tactic of the virus.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Address><Antibodies><Antibody Response><Binding><Binding Proteins><Biological><C Type Lectin Receptors><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><CLG4B><COVID crisis><COVID epidemic><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infected patient><COVID-19 infection><COVID-19 pandemic><COVID-19 patient><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 virus><COVID-19 virus infection><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><COVID19 virus><CV-19><CV19><Cancer Treatment><Cell Body><Cell Communication and Signaling><Cell Degranulation><Cell Function><Cell Process><Cell Signaling><Cell physiology><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cellular Stress><Cellular Stress Response><Classification><Clinical Treatment Moab><CoV-2><CoV2><Collaborations><Coronaviridae><Coronavirus><Cytotoxic cell><Data><Diagnosis><Disease Outcome><Down-Regulation><Family><GELB><Gene Transcription><Genes><Genetic><Genetic Alteration><Genetic Change><Genetic Transcription><Genetic defect><Hepatitis Viruses><Herpesviridae><Herpesviruses><Histocompatibility Complex><Histocompatibility Complices><Human><Immune><Immune Globulins><Immune Response Genes><Immune mediated therapy><Immune response><Immunes><Immunity><Immunoglobulins><Immunological response><Immunologically Directed Therapy><Immunotherapy><Impairment><In Vitro><Individual><Infection><Influenza Virus><Intracellular Communication and Signaling><Investigators><Ir Gene><K Cells><K lymphocyte><Killer Cells><LYT3><Ligand Binding Protein><Ligand Binding Protein Gene><Ligands><Lymphatic cell><Lymphocyte><Lymphocytic><Lytotoxicity><MMP9><MMP9 gene><Major Histocompatibility Complex><Major Histocompatibility Complices><Malignant><Malignant - descriptor><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Mediating><Messenger RNA><Modern Man><Molecular><Molecular Interaction><Monoclonal Antibodies><Mutation><NK Cells><Natural Killer Cells><Oncogenesis><Pathogenesis><Prevention><Protein Binding><Proteins><RNA Expression><Receptor Down-Regulation><Receptor Protein><Research><Research Personnel><Researchers><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sarbecovirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Severity of illness><Signal Transduction><Signal Transduction Systems><Signaling><Subcellular Process><Surface><Systematics><T cell response><T-Cell Subsets><T-Lymphocyte Subsets><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><Testing><Transcription><Transfection><Vaccination><Variant><Variation><Viral><Viral Diseases><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Virus><Virus Diseases><Wuhan coronavirus><anti-cancer therapy><anticancer therapy><biologic><biological signal transduction><bound protein><cancer cell><cancer therapy><cancer-directed therapy><cell killing><cell stress><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus patient><cytotoxic><cytotoxicity><disease severity><genetic association><genetic resistance><genome mutation><hCoV19><herpes virus><host response><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><influenzavirus><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><lung heterograft><lung xenograft><lymph cell><mAbs><mRNA><monoclonal Abs><nCoV2><neutralizing antibody><new approaches><novel><novel approaches><novel strategies><novel strategy><pandemic effect><pandemic impact><pandemic outcome><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><pre-clinical study><preclinical study><receptor><receptor downregulation><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><social role><tumorigenesis><variants of concern><viral infection><virtual><virus infection><virus protein><virus-induced disease>